|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
BEFREE |
FADD deficiency sensitized more efficiently for TNFR1-mediated necroptosis than caspase-8 deficiency pointing to a caspase-8 independent inhibitory activity of FADD on TNF-induced necroptosis.
|
30741924 |
2019 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
BEFREE |
Mixed bone marrow chimeric mice demonstrate that caspase-8 deficiency does not confer preferential expansion of synovial macrophage and dendritic cell populations, nor do caspase-8-deficient synovial populations succumb to RIPK3-mediated necroptotic death.
|
28978351 |
2017 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
GermlineCausalMutation
|
disease |
ORPHANET |
Advances in autoimmune lymphoproliferative syndromes.
|
21447005 |
2011 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
AlteredExpression
|
disease |
BEFREE |
Studies of patients with autoimmune lymphoproliferative syndrome (ALPS) or caspase-8 deficiency state (CEDS) demonstrated the ability of gene expression microarray analyses and small interfering RNAs (siRNA) to establish the physiologically important roles of NRAS, caspase-10, and caspase-8 for normal lymphocyte apoptosis and activation.
|
18818883 |
2009 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
GermlineCausalMutation
|
disease |
ORPHANET |
Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome.
|
16446975 |
2006 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
GeneticVariation
|
disease |
UNIPROT |
Thus, caspase-8 deficiency in humans is compatible with normal development and shows that caspase-8 has a postnatal role in immune activation of naive lymphocytes.
|
12353035 |
2002 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
BEFREE |
Thus, caspase-8 deficiency in humans is compatible with normal development and shows that caspase-8 has a postnatal role in immune activation of naive lymphocytes.
|
12353035 |
2002 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
MGD |
|
|
|
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrated that ASB3 can regulate mitochondrial pathway of apoptosis by controlling caspase-8 mediated cleavage of Beclin1 in HCC.
|
31016535 |
2019 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
It suggests that PAK4 as target is a switch between caspase-8 apoptosis and NF-κB survival signals induced by TNF-α in hepatocarcinoma cells.
|
30149917 |
2018 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
On the whole, the present study revealed a molecular link between the three‑miRNA signature, comprising miR‑371-5p, miR‑373 and miR‑543, and the negative necroptotic regulator Casp‑8, and presents evidence for its employment as a novel potential diagnostic, prognostic and therapeutic target in HCC.
|
29845207 |
2018 |
|
Liver carcinoma
|
0.900 |
Therapeutic
|
disease |
RGD |
Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor activity in thioacetamide-induced hepatocellular carcinoma model.
|
29133031 |
2018 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Moreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8 hyperactivation but also impaired NF-κB activation, promoting the spontaneous development of hepatocellular carcinoma.
|
28017612 |
2017 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Here, we mechanistically link caspase-8-dependent apoptosis to HCC development via proliferation- and replication-associated DNA damage.
|
28898696 |
2017 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
ANP32B knockdown by siRNA altered the expression of apoptosis-related proteins in HCC cell lines and reduced the expression of cleaved forms of caspase 3 and caspase 9, but not that of caspase 8, in HCC cells cultured with the pro-apoptotic agent staurosporine.
|
28486557 |
2017 |
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the CASP8 -652 6N ins/del polymorphism may play a protective role in the development, progression, and survival of HBV-related HCC among the Chinese Han population.
|
28643196 |
2017 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We found that the oncolytic adenoviruses Ad·AFP·D55-IL-24 and Ad·AFP·D55-TRAIL express tumor-suppressor gene interleukin-24 (IL-24) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), respectively, significantly suppressed the HCC cell growth in vitro by inducing apoptosis by the caspase-8 and mitochondria-dependent caspase-9 signaling pathways.
|
21979578 |
2012 |
|
Liver carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
This study has investigated whether galangin, a flavonol derived from Alpinia officinarum Hance and used as food additives in southern China, induces apoptosis in hepatocellular carcinoma cells (HCCs) by activation of the caspase-8 and Bid pathway.
|
22575016 |
2012 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Targeted stimulation of the caspase-8 promoter by interferons alpha and gamma, cytotoxic drugs or p53 can substantially sensitize hepatoma cells for apoptosis, whereas hepatocellular carcinoma frequently present an inactive caspase-8 gene promoter.
|
22153863 |
2012 |
|
Liver carcinoma
|
0.900 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation of the caspase 8 and survivin gene was analyzed in 73 primary HCC using methylation-specific polymerase chain reaction.
|
20403046 |
2010 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.
|
19728331 |
2010 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
LHGDN |
P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes.
|
17224200 |
2007 |
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Caspase-8 is frequently mutated or silenced in several tumors including hepatocellular carcinomas (HCC) thereby potentially contributing to chemoresistance.
|
17922191 |
2007 |